Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 5/20 | 0.63 |
| ▸ | CASP6 | P55212 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.55 |
| ▸ | MAPT | P10636 | 10/20 | 0.55 |
| ▸ | GAA | P10253 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL854196 | 0.93 | GFER (0.71) | GFERCASP6ALDH1A1MAPTGAA | |
| SCHEMBL3548441 | 0.85 | GFER (0.87) | GFERCASP6ALDH1A1MAPTGAA | |
| SCHEMBL22805291 | 0.83 | AKR1C3 (0.58) | ALDH1A1MAPTGAAHTTKMT2A | |
| SCHEMBL4985735 | 0.83 | AKR1C3 (0.68) | GFERCASP6ALDH1A1MAPTGAA | |
| SCHEMBL18155100 | 0.83 | IP6K1 (0.55) | GFERCASP6ALDH1A1MAPTGAA | |
| SCHEMBL112440 | 0.82 | MAPT (0.78) | GFERCASP6ALDH1A1MAPTGAA | |
| SCHEMBL2452376 | 0.81 | GFER (0.56) | GFERCASP6ALDH1A1MAPTGAA | |
| SCHEMBL3216413 | 0.81 | TDP1 (0.66) | GFERCASP6ALDH1A1MAPTGAA | |
| SCHEMBL15271347 | 0.81 | ALDH1A1 (0.71) | GFERCASP6ALDH1A1MAPTGAA | |
| SCHEMBL28806386 | 0.80 | GFER (0.73) | GFERCASP6ALDH1A1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880664-A1 | LOX INHIBITORS | The Institute of Cancer Research: Royal Cancer Hospital (GB) | 2021-09-22 | — | — | EP | disclosed |
| WO-2020099886-A1 | LOX INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-05-22 | — | — | WO | disclosed |
| US-8343988-B2 | Inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V (BE) | 2013-01-01 | — | — | US | disclosed |
| US-8268833-B2 | Inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA, N.V. (BE) | 2012-09-18 | — | — | US | disclosed |
| EP-1485353-B1 | NEW INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-24 | — | — | EP | disclosed |
| US-7816363-B2 | to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC | JANSSEN PHARMACEUTICA, N.V. (BE) | 2010-10-19 | — | — | US | disclosed |
| WO-2010055304-A2 | PHARMACEUTICAL COMPOUNDS | SAREUM LIMITED (GB) | 2010-05-20 | — | — | WO | disclosed |
| EP-2170849-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | Sareum Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| US-20090170836-A1 | NEW INHIBITORS OF HISTONE DEACETYLASE | ANGIBAUD PATRICK RENE | 2009-07-02 | — | — | US | disclosed |
| US-20090170881-A1 | NEW INHIBITORS OF HISTONE DEACETYLASE | ANGIBAUD PATRICK RENE | 2009-07-02 | — | — | US | disclosed |
| WO-2008139161-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| US-20050107384-A1 | to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC | ORTHO-MCNEIL PHARMACEUTICAL INC. | 2005-05-19 | — | — | US | disclosed |
| EP-1485353-A1 | NEW INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003076400-A1 | NEW INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107384-A1 | to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a HDAC in a biological sample comprising detecting or measuring the formation of a complex between a labelled compound as defined in claim (I) and a HDAC | HDAC1, HDAC11, HDAC5 | GFER 4356/4885CASP6 437/4885ALDH1A1 1048/4885 |
| US-20090170836-A1 | NEW INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | GFER 3634/4885CASP6 2329/4885ALDH1A1 1650/4885 |
| US-20090170881-A1 | NEW INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC3, HDAC11 | GFER 3634/4885CASP6 2329/4885ALDH1A1 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.